Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Secondary iron overload.

J P Kushner1, J P Porter, N F Olivieri

  • 1Department of Hematology, University College London, 98 Chenies Mews, London WC1 6HX.

Hematology. American Society of Hematology. Education Program
|November 28, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deferiprone-Induced Agranulocytosis : A Critical Review of Five Rechallenged Cases.

Clinical drug investigation·2016
Same author

Analysis and expansion of the eosinophilic esophagitis transcriptome by RNA sequencing.

Genes and immunity·2014
Same author

Pharmacokinetics of arginine butyrate in patients with hemoglobinopathy.

Environmental toxicology and pharmacology·2011
Same author

The heme biosynthesis pathway and clinical manifestations of abnormal function.

Current protocols in toxicology·2010
Same author

Measurement of uroporphyrinogen decarboxylase activity.

Current protocols in toxicology·2010
Same author

Structural and kinetic characterization of mutant human uroporphyrinogen decarboxylases.

Cellular and molecular biology (Noisy-le-Grand, France)·2009

Managing secondary iron overload from chronic transfusion therapy is crucial for patients with anemias. This review covers iron chelation strategies, including deferoxamine administration and oral chelators, to improve patient outcomes.

Area of Science:

  • Hematology
  • Pharmacology

Background:

  • Chronic transfusion therapy improves quality of life and survival for patients with inherited anemias and acquired refractory anemias.
  • Secondary iron overload is a significant complication of chronic transfusion therapy, leading to organ damage (heart, liver).

Purpose of the Study:

  • To review the use of iron chelating agents in managing transfusion-induced secondary iron overload.
  • To provide guidelines for chelation therapy in chronically transfused adults and discuss optimal timing for initiation.

Main Methods:

  • Review of deferoxamine administration techniques to optimize pharmacokinetics and minimize toxicity.
  • Examination of clinical consequences of iron overload and criteria for initiating chelation therapy.
  • Discussion of clinical trials evaluating orally administered iron chelators.

Related Experiment Videos

Main Results:

  • Deferoxamine administration can be optimized for efficacy and safety.
  • Optimal timing for initiating chelation therapy is critical for managing iron overload.
  • Oral iron chelators are under evaluation for improved patient compliance and efficacy.

Conclusions:

  • Iron chelation therapy is essential for managing secondary iron overload in chronically transfused patients.
  • Optimized administration of existing chelators and development of oral agents are key to improving long-term outcomes.